These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
254 related items for PubMed ID: 25469036
1. Glytan decreases portal pressure via mesentery vasoconstriction in portal hypertensive rats. Du QH, Han L, Jiang JJ, Xu Y, Li WH, Li PT, Wang XY, Jia X. World J Gastroenterol; 2014 Nov 28; 20(44):16674-82. PubMed ID: 25469036 [Abstract] [Full Text] [Related]
2. Increased endothelin receptor B and G protein coupled kinase-2 in the mesentery of portal hypertensive rats. Du QH, Han L, Jiang JJ, Li PT, Wang XY, Jia X. World J Gastroenterol; 2013 Apr 07; 19(13):2065-72. PubMed ID: 23599626 [Abstract] [Full Text] [Related]
3. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. Reiberger T, Payer BA, Schwabl P, Hayden H, Horvatits T, Jäger B, Hummel T, Mitterhauser M, Trauner M, Fuhrmann V, Angermayr B, Peck-Radosavljevic M, Vienna Hepatic Hemodynamic Lab. Liver Int; 2013 Apr 07; 33(4):561-8. PubMed ID: 23331709 [Abstract] [Full Text] [Related]
4. Increased expression of endothelin receptors in the vasculature of portal hypertensive rats: role in splanchnic hemodynamics. Cahill PA, Hou MC, Hendrickson R, Wang YN, Zhang S, Redmond EM, Sitzman JV. Hepatology; 1998 Aug 07; 28(2):396-403. PubMed ID: 9696003 [Abstract] [Full Text] [Related]
5. Effects of Nuclear Factor-E2-related factor 2/Heme Oxygenase 1 on splanchnic hemodynamics in experimental cirrhosis with portal hypertension. Qin J, He Y, Duan M, Luo M. Microvasc Res; 2017 May 07; 111():12-19. PubMed ID: 28025064 [Abstract] [Full Text] [Related]
6. Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction. Moleda L, Trebicka J, Dietrich P, Gäbele E, Hellerbrand C, Straub RH, Sauerbruch T, Schoelmerich J, Wiest R. Gut; 2011 Aug 07; 60(8):1122-32. PubMed ID: 21317421 [Abstract] [Full Text] [Related]
7. The beneficial effects of curcumin in cirrhotic rats with portal hypertension. Hsu SJ, Lee JY, Lin TY, Hsieh YH, Huang HC, Lee FY, Lin HC, Hou MC, Lee SD. Biosci Rep; 2017 Dec 22; 37(6):. PubMed ID: 29162665 [Abstract] [Full Text] [Related]
8. Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure. Theodorakis NG, Wang YN, Korshunov VA, Maluccio MA, Skill NJ. World J Gastroenterol; 2015 Apr 14; 21(14):4126-35. PubMed ID: 25892862 [Abstract] [Full Text] [Related]
9. Murine study of portal hypertension associated endothelin-1 hypo-response. Theodorakis N, Maluccio M, Skill N. World J Gastroenterol; 2015 Apr 28; 21(16):4817-28. PubMed ID: 25944995 [Abstract] [Full Text] [Related]
10. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats. Coll M, Rodriguez S, Raurell I, Ezkurdia N, Brull A, Augustin S, Guardia J, Esteban R, Martell M, Genescà J. Hepatology; 2012 Nov 28; 56(5):1849-60. PubMed ID: 22610782 [Abstract] [Full Text] [Related]
11. NADPH oxidase 1/4 inhibition attenuates the portal hypertensive syndrome via modulation of mesenteric angiogenesis and arterial hyporeactivity in rats. Deng W, Duan M, Qian B, Zhu Y, Lin J, Zheng L, Zhang C, Qi X, Luo M. Clin Res Hepatol Gastroenterol; 2019 Jun 28; 43(3):255-265. PubMed ID: 30413372 [Abstract] [Full Text] [Related]
12. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. Reiberger T, Angermayr B, Schwabl P, Rohr-Udilova N, Mitterhauser M, Gangl A, Peck-Radosavljevic M. J Hepatol; 2009 Nov 28; 51(5):865-73. PubMed ID: 19726100 [Abstract] [Full Text] [Related]
13. Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. Schwabl P, Payer BA, Grahovac J, Klein S, Horvatits T, Mitterhauser M, Stift J, Boucher Y, Trebicka J, Trauner M, Angermayr B, Fuhrmann V, Reiberger T, Peck-Radosavljevic M. J Hepatol; 2014 Jun 28; 60(6):1135-42. PubMed ID: 24530596 [Abstract] [Full Text] [Related]
14. Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats. Huang HC, Wang SS, Hsin IF, Chang CC, Lee FY, Lin HC, Chuang CL, Lee JY, Hsieh HG, Lee SD. Hepatology; 2012 Jul 28; 56(1):248-58. PubMed ID: 22290687 [Abstract] [Full Text] [Related]
17. Simvastatin effects on portal-systemic collaterals of portal hypertensive rats. Huang HC, Wang SS, Lee JY, Chen YC, Lee FY, Lin HC, Chang CC, Lee SD. J Gastroenterol Hepatol; 2010 Aug 28; 25(8):1401-9. PubMed ID: 20659230 [Abstract] [Full Text] [Related]
18. Defective endothelial nitric oxide synthase signaling is mediated by rho-kinase activation in rats with secondary biliary cirrhosis. Anegawa G, Kawanaka H, Yoshida D, Konishi K, Yamaguchi S, Kinjo N, Taketomi A, Hashizume M, Shimokawa H, Maehara Y. Hepatology; 2008 Mar 28; 47(3):966-77. PubMed ID: 18167063 [Abstract] [Full Text] [Related]
19. Neuropeptide Y restores non-receptor-mediated vasoconstrictive action in superior mesenteric arteries in portal hypertension. Hartl J, Dietrich P, Moleda L, Müller-Schilling M, Wiest R. Liver Int; 2015 Dec 28; 35(12):2556-63. PubMed ID: 26010514 [Abstract] [Full Text] [Related]
20. Combined administration of propranolol + AG490 offers better effects on portal hypertensive rats with cirrhosis. Wang D, Wang Q, Yin J, Dong R, Wang Q, Du X, Lu J. J Gastroenterol Hepatol; 2016 May 28; 31(5):1037-44. PubMed ID: 26487394 [Abstract] [Full Text] [Related] Page: [Next] [New Search]